|
|
Article: Oscient Pharmaceuticals to Present Clinical Data on FACTIVE(R) Tablets at Chest 2005; Data Presentations Address Utility of FACTIVE in High-Risk Patients and against Resistant Infections.
- Article from:
- Business Wire
- Article date:
- October 31, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WALTHAM, Mass. -- - Four poster presentations highlighting data from Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, are being presented at CHEST 2005, the Annual Meeting of the American College of Chest Physicians (ACCP). Included in the program are data exploring the clinical activity of FACTIVE in treating acute bacterial exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) in patients with risk factors and co-morbidities and respiratory tract infections caused by resistant bacteria.
"The data in these posters reinforce the use of FACTIVE, the most potent ...